← All trials

NCT05132569

Phase 3Interventional

Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.

View on ClinicalTrials.gov ↗

Timeline

Start date
Nov 19, 2021
Primary completion
Nov 25, 2024
Completion date
Dec 22, 2026
First posted
Nov 24, 2021
Last posted
Nov 24, 2021
Enrollment
154
Arms / groups
2 / —
Source
AACT · ingestion pipeline

Sponsors

Drugs studied

Indications studied

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.